Min Young Lee1, Eun Young Kim2, Se Hyun Kim3, Kyung-Cho Cho4, Kyooseob Ha5, Kwang Pyo Kim6, Yong Min Ahn7. 1. Institute for Systems Biology, Seattle, WA, United States; Department of Applied Chemistry, College of Applied Science, Kyung Hee University, Yongin, Republic of Korea. 2. Department of Psychiatry, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea. 3. Department of Neuropsychiatry, Dongguk University Medical School, Dongguk University International Hospital, Goyang, Republic of Korea. 4. Department of Applied Chemistry, College of Applied Science, Kyung Hee University, Yongin, Republic of Korea. 5. Department of Psychiatry, Seoul National University Bundang Hospital, Seongnam, Republic of Korea;; Seoul National Hospital, Seoul, Republic of Korea; Institute of Human Behavioral Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. 6. Department of Applied Chemistry, College of Applied Science, Kyung Hee University, Yongin, Republic of Korea. Electronic address: kimkp@khu.ac.kr. 7. Department of Psychiatry, Seoul National University Hospital, Seoul, Republic of Korea; Institute of Human Behavioral Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: aym@snu.ac.kr.
Abstract
OBJECTIVE: Major depressive disorder (MDD) is a systemic and multifactorial disorder involving complex interactions between genetic predisposition and disturbances of various molecular pathways. Its underlying molecular pathophysiology remains unclear, and no valid and objective diagnostic tools for the condition are available. METHODS: We performed large-scale proteomic profiling to identify novel peripheral biomarkers implicated in the pathophysiology of MDD in 25 drug-free female MDD patients and 25 healthy controls. First, quantitative serum proteome profiles were obtained and analyzed by liquid chromatography-tandem mass spectrometry using serum samples from 10 MDD patients and 10 healthy controls. Next, candidate biomarker sets, including differentially expressed proteins from the profiling experiment and those identified in the literature, were verified using multiple-reaction monitoring in 25 patients and 25 healthy controls. The final panel of potential biomarkers was selected using multiparametric statistical analysis. RESULTS: We identified a serum biomarker panel consisting of six proteins: apolipoprotein D, apolipoprotein B, vitamin D-binding protein, ceruloplasmin, hornerin, and profilin 1, which could be used to distinguish MDD patients from controls with 68% diagnostic accuracy. Our results suggest that modulation of the immune and inflammatory systems and lipid metabolism are involved in the pathophysiology of MDD. CONCLUSIONS: Our findings of functional proteomic changes in the peripheral blood of patients with MDD further clarify the molecular biological pathway underlying depression. Further studies using larger, independent cohorts are needed to verify the role of these candidate biomarkers for the diagnosis of MDD.
OBJECTIVE: Major depressive disorder (MDD) is a systemic and multifactorial disorder involving complex interactions between genetic predisposition and disturbances of various molecular pathways. Its underlying molecular pathophysiology remains unclear, and no valid and objective diagnostic tools for the condition are available. METHODS: We performed large-scale proteomic profiling to identify novel peripheral biomarkers implicated in the pathophysiology of MDD in 25 drug-free female MDDpatients and 25 healthy controls. First, quantitative serum proteome profiles were obtained and analyzed by liquid chromatography-tandem mass spectrometry using serum samples from 10 MDDpatients and 10 healthy controls. Next, candidate biomarker sets, including differentially expressed proteins from the profiling experiment and those identified in the literature, were verified using multiple-reaction monitoring in 25 patients and 25 healthy controls. The final panel of potential biomarkers was selected using multiparametric statistical analysis. RESULTS: We identified a serum biomarker panel consisting of six proteins: apolipoprotein D, apolipoprotein B, vitamin D-binding protein, ceruloplasmin, hornerin, and profilin 1, which could be used to distinguish MDDpatients from controls with 68% diagnostic accuracy. Our results suggest that modulation of the immune and inflammatory systems and lipid metabolism are involved in the pathophysiology of MDD. CONCLUSIONS: Our findings of functional proteomic changes in the peripheral blood of patients with MDD further clarify the molecular biological pathway underlying depression. Further studies using larger, independent cohorts are needed to verify the role of these candidate biomarkers for the diagnosis of MDD.
Authors: Josephine C McGowan; Collin Hill; Alessia Mastrodonato; Christina T LaGamma; Alexander Kitayev; Rebecca A Brachman; Niven R Narain; Michael A Kiebish; Christine A Denny Journal: Neuropsychopharmacology Date: 2018-03-29 Impact factor: 7.853
Authors: Lívia Ramos-da-Silva; Pamela T Carlson; Licia C Silva-Costa; Daniel Martins-de-Souza; Valéria de Almeida Journal: Complex Psychiatry Date: 2021-07-09
Authors: Christoph W Turck; Paul C Guest; Giuseppina Maccarrone; Marcus Ising; Stefan Kloiber; Susanne Lucae; Florian Holsboer; Daniel Martins-de-Souza Journal: Front Mol Neurosci Date: 2017-08-31 Impact factor: 5.639
Authors: Ashley L Comes; Sergi Papiol; Thorsten Mueller; Philipp E Geyer; Matthias Mann; Thomas G Schulze Journal: Transl Psychiatry Date: 2018-08-16 Impact factor: 6.222
Authors: Sung Yeon Sarah Han; Jason D Cooper; Sureyya Ozcan; Nitin Rustogi; Brenda W J H Penninx; Sabine Bahn Journal: Transl Psychiatry Date: 2019-11-07 Impact factor: 6.222
Authors: Mike C Jentsch; Huibert Burger; Marjolein B M Meddens; Lian Beijers; Edwin R van den Heuvel; Marcus J M Meddens; Robert A Schoevers Journal: Int J Mol Sci Date: 2020-04-25 Impact factor: 5.923